Docstoc

The Dermatology market Outlook to acne

Document Sample
The Dermatology market Outlook to  acne Powered By Docstoc
					The Dermatology Market
Outlook to 2011
A new report from Business Insights...




• Quantify patient potential, assess
  treatment trends and sales patterns.




• Forecast sales of the major products in
  the dermatology area over the period
  2006-11.



• Evaluate market share of leading
  companies, such as Novartis,
  GlaxoSmithKline and Bayer Schering
  Pharma.
                                                                                                                                              B u s i n e s s I n s i g h ts                             1




The Dermatology Market Outlook to 2011

Introduction                                                                                                      Figure 3.19: The dermatology pipeline by
                                                                                                                indication and stage of development, 2006

                                                                                                              Stasis Dermatitis
                                                                                                                   Photoaging                                               PC    I     II   III    PA   A
The Dermatology Market Outlook to 2011 provides detailed analysis                          Tinea Pedis (Athlete's Foot)
                                                                                                                 Photodamage
on 5 indications within the dermatology market, identifying high growth                                      Contact Dermatitis
                                                                                                                     Rosacea
brands, future market leaders and key drug classes.                                                                 Skin Aging




                                                                             Indications
                                                                                                                   Dermatosis
                                                                                                         Seborrheic Dermatitis
                                                                                                                Skin Infections
The in-depth 6-year epidemiology and product sales forecasts in this                                               Skin Itching


report will enable you to plan effectively, evaluate changes in the                                                      Scar
                                                                                                                Skin Disorders

competitive positions of leading companies and accurately benchmark                                            Onychomycosis
                                                                                                                         Acne

your performance.                                                                                                    Psoriasis

                                                                                                                                  0      20       40         60        80         100              120       140

                                                                                                                     Number
                                                                             Source: The Dermatology Market Outlook to 2011of candidates

The 5 Major dermatological indications covered are:                          Phases of Development:
                                                                             PC= Preclinical; I= Phase I; II= Phase II; III =Phase III; PA=
                                                                             Pending approval; A= Approved
               •       Acne
                                                                                 "Of all indications in the dermatology area,
               •       Psoriasis                                                  psoriasis represents the key development
                                                                             opportunity for drug development companies, with
                                                                             119 compounds estimated to be in development..."
               •       Infectious diseases of the skin

               •       Dermatitis

               •       Rosacea




                                                                                                             Figure 2.5: Competitive dynamics of the global
                                                                                                                dermatology market by drug class, 2005

Key findings of this new report                                                                        12%
                                                                                                                                      Psoriasis treatments
                                                                                                       10%
                                                                                                                                                                            Corticosteroids
• The psoriasis market is forecast to post the most aggressive                                         8%

                                                                                                       6%
  growth rates over the period to 2011, as Raptiva and Daivobet
                                                                                    Sales growth (%)




                                                                                                       4%

  drive growth over the forecast period. Psoriasis treatments are set to                               2%                                                                                Anti-infectives
                                                                                                                                                              Acne treatments
  expand sales at a CAGR of 12.5%, reaching sales of $1.9bn in 2011.                                   0%
                                                                                                                       5%             10%         15%         20%           25%              30%         35%
                                                                                                       -2%                                                        Market share (%)

• With Roaccutane and Diane facing generic competition, the                                            -4%
                                                                                                                                                  Others
  branded oral acne treatments market is set to decline over the                                       -6%
                                                                                                                                                                     Bubble size represents 2005
  forecast period. Forecast sales of the acne market are estimated at                                                                                                sales

  $2.7bn in 2011.
                                                                                                 "Although the market for psoriasis products
• The corticosteroid market was valued at $2,783m in 2005, 5.8%                              features robust levels of sales growth, up by 10.5%
  up on year previous sales of $2,630m. Triple combination                                   from $833m in 2004 to $921m in 2005, the market
  anti-infective/corticosteroid therapies are driving growth, whilst                             is small, comprising only 8.2% of the entire
                                                                                                            dermatology market...”
  widespread genericization is restraining growth of the class as a whole.
                                                                                                                                 B u s i n e s s I n s i g h ts                  2




The Dermatology Market Outlook to 2011

                                                                                      Figure 2.3: Global dermatology market share by
Your questions answered                                                                                geography, 2005
                                                                                                             Rest of World




• What will be the major growth indications in the dermatology area over              1% Poland                                 19%

                                                                                 1% Russia
  the period 2006-11?                                                            1% Australia
                                                                                                                                                                            US
                                                                                                                                                                  41%
                                                                                             India
                                                                                                                  2%
                                                                                            S. Korea              2%                       $11.2bn
• How have recent major launches from companies such as Novartis,                            Spain
                                                                                                                  3%
                                                                                                                   3%
  Astellas and Genentech performed?                                                             Canada
                                                                                                                     3%
                                                                                                                           3%
                                                                                                     Italy
                                                                                                                                4%
                                                                                                                                      4%             8%
• Which companies will become the key players in the dermatology area                                        UK                              5%

                                                                                                                  Brazil
  over the period 2006-11?                                                                                                      France                    Japan
                                                                                                                                           Germany

                                                                                Source: The Dermatology Market Outlook to 2011

• Which products will be impacted by generic competitors over the
  period 2006-11?                                                                  "In terms of size, the US market dominates the
                                                                                  global dermatology market, responsible for some
• What will the competitive landscape in acne, psoriasis, dermatitis,                   41.2% of sales or $4,615m in 2005..."

  rosacea, viral, bacterial and fungal dermatological infections look like in
  2011?




                                                                                  Figure 3.20: Leading recently launched products and
This report will enable you to...                                                    late-stage R&D in the dermatology market, 2005

                                                                                  rambazole

                                                                                BG-12/Panaclar

• Quantify patient potential, assess treatment trends and sales                   Altabax


  patterns with this report’s in-depth coverage of the 5 major                    Desonate

                                                                                    Humira
  dermatological indications, the US, Japanese and top EU 5 markets and            Remicade

  the top 10 leading companies.                                                    Oracea

                                                                                   Taclonex

                                                                                    Ziana

• Forecast sales of the major products in the dermatology area over                Zostavax



  the period 2006-11 in major dermatological indications, classes of                                     Phase II                    Phase III       Registration       Marketed


  treatments and by company.
                                                                                Source: Healthy, Overweight and Obese Consumers



• Evaluate how market share of leading companies, such as Novartis,
                                                                                "Barrier Therapeutics is currently conducting Phase
  GlaxoSmithKline and Schering Plough, will change over the next 6
                                                                                    IIb clinical trials in the US for its compound,
  years, and assess your competitive position within the market.                rambazole, indicated for the treatment of moderate
                                                                                     to severe acne. Rambazole, a retinoic acid
• Discover which indications have the greatest potential to provide             metabolism blocking agent (RAMBA) is a strong and
                                                                                  highly selective inhibitor of RA 4-hydroxylase..."
  franchise growth and understand the growth drivers of major classes
  of dermatological treatments including corticosteroids, anti-infectives,
  acne treatments and psoriasis treatments.
Sample Information                                                                                                                                 B u s i n e s s I n s i g h ts   3




Chapter 4: Competitive Landscape
Sales focus by drug class

2005 sales from Novartis’ dermatology portfolio by drug class are illustrated in Figure 4.22.

The highest sales accrued in 2005 were by the ‘others’ drug class of which Elidel was the highest contributor, having recorded sales of
$314m for the same year. Novartis’ dermatology portfolio mainly comprises of the company’s generic versions of products such as eurax
hydrochloride, econazole and ketoconazole. While corticosteroids accrued $4m in sales, topical acne products contributed a mere $2m
                                                                                            towards total sales.

                                 Figure 4.22: Novartis’ dermatology sales, 2005                                                Marketed product portfolio
                                                                                                                               Table 4.37 displays Novartis’ marketed
                                                                                                                               products in its dermatology franchise. Sales
                     400                                                                            378                        for 2004 and 2005 are shown, together with
                     350                                                                                                       US patent expiry dates.
  Sales, 2005 ($m)




                                                                                                                               Novartis’ dermatology franchise features two
                     300
                                                                                                                               major products, Elidel (pimecrolimus),
                     250
                                                                                                                               indicated for the treatment of eczema, and
                              196
                     200                                                                                                       Lamisil (terbinafine), indicated for the
                     150                                                                                                       treatment of fungal infections. Collectively,
                     100                                                                                                       both products contributed $469m in sales in
                                                                                                                               2005, or 79.1% of Novartis’ dermatology
                     50
                                                  4                    2                                                       revenues. The remainder of Novartis’
                     -                                                                                                         marketed product portfolio features a limited
                           Anti-infectives    Corticosteroids    Topical acne product             Others
                                                         Drug Classes                                                          number of growth brands, the most
                                                                                                                               prominent of which is Denavir, an anti-viral
                                                                                                                               acquired from GSK in 2000 following the
                               Source: The Dermatology Market Outlook to 2011
                                                                                                                               merger of SmithKlineBeecham and
                                                                                                                               GlaxoWellcome. Denavir has not performed

brightly, under competition from OTC anti-virals,
the most prominent of which is also marketed                                         Table 4.37: Novartis’ dermatology product portfolio, 2004-5
by GSK under the brand name Zovirax.
Outside of Novartis’ range of branded products,                                                                                                                        Sales
                                                                           Brand        Generic                          US patent expiry          Sales ($m)          growth
Novartis markets a number of generic products,
                                                                                                                                             2004         2005
some of which saw growth in 2005, but all of
                                                                           Elidel       pimecrolimus                     2016                405          314          -26.6%
which feature limited sales potential, given the
                                                                           Lamisil      terbinafine                      2006                144          155          4.5%
extent of generic competition present in the
                                                                           Denavir      penciclovir                      2015                23           27           13.5%
market. With sales decreasing by 8.2% in 2005, a
                                                                           n/a          erythromycin/ benzoyl peroxide   n/a                 7            13           78.0%
strategic goal for Novartis is to halt the decline in
                                                                           Desenex      undecylenic acid                 exp                 5            5            -10.8%
revenues for 2006 onwards. However, clinical trials
                                                                           n/a          ketoconazole                     n/a                 1            5            671.2%
that can better establish the safety of Elidel are                         n/a          econazole                        n/a                 3            4            30.0%
warranted, following an FDA advisory associating                           n/a          eurax                            n/a                 4            4            -6.3%
the product with a higher risk of lymphoma.                                             hydrocortisone



                                                                           Others                                                            51           65           27.7%
                                                                           Total                                                             646          593          -8.2%


                                                                                        Source: The Dermatology Market Outlook to 2011




Order today to find out more...
Table of Contents                                                                                           B u s i n e s s I n s i g h ts   4




The Dermatology Market Outlook to 2011

  CHAPTER 1: PATIENT POTENTIAL                                                         CHAPTER 3: PIPELINE ANALYSIS
  • Summary                                      - Continued approvals for biologic    • Summary
  • Introduction                                   agents in the treatment of          • Introduction
  • Acne                                           psoriasis                           • Key trends in R&D
     - Overview                                  - Black box warnings for Elidel and
                                                                                          - New mechanism of action
     - Diagnosis, treatment and                    Protopic
                                                                                          - Reformulations
     management                                  - Safety concerns over Roaccutane
                                                                                          - Combination drugs
     - Epidemiology                                gain more traction
     - Forecast epidemiology                 •   Acne treatments                          - Biologics
  • Psoriasis                                    - Market analysis by drug class       • The therapeutic area pipeline
     - Overview                                  - Competitive dynamics of acne        • Leading drugs in development
     - Diagnosis, treatment and                    treatments                          • Profiles of key pipeline products
       management                                - Leading acne treatment brands          - Phase II compounds
     - Epidemiology                              - Oral acne treatments market                - rambazole
     - Forecast epidemiology                       analysis                               - Phase III compounds
  • Infectious diseases of the skin                  - Market dynamics                        - Panaclar/BG-12
     - Overview                                      - Key brands analysis
                                                                                              - CNTO 1275 interleukin antagonist
        - Bacterial infections of the skin       - Topical acne treatments market
                                                                                          - Drugs in registration
        - Fungal infections of the skin            analysis
                                                                                              - Altabax (retapamulin)
        - Viral infections of the skin               - Market dynamics
     - Diagnosis, treatment and                      - Key brands analysis                    - Desonate (desonide)
       management                                - Acne treatment sales forecasts to      - Recently marketed drugs
     - Epidemiology                                2011                                       - Humira (adalimumab)
        - Viral skin infections              •   Psoriasis treatment                          - Oracea (doxycycline extended
        - Fungal skin infections                 - Market analysis by drug class          release sub anti-microbial dose)
        - Bacterial skin infections              - Competitive dynamics of psoriasis          - Remicade (infliximab)
     - Forecast epidemiology                       treatment classes                          - Taclonex
        - Viral skin infections                  - Leading brands of psoriasis                  (calcipotriene/betamethasone)
        - Fungal skin infections                   treatments
                                                                                              - Ziana (clindamycin/tretinoin)
        - Bacterial skin infections                  - Market dynamics
                                                                                       • Pipeline forecasts
  • Dermatitis                                       - Key brands analysis
                                                                                          - Factors affecting forecasts
     - Overview                                  - Psoriasis treatments sales
     - Diagnosis, treatment and                    forecasts to 2011                      - Dermatology pipeline forecasts
       management                            •   Corticosteroid treatments
     - Epidemiology                              - Market analysis by drug class       CHAPTER 4: COMPETITIVE LANDSCAPE
     - Forecast epidemiology                     - Competitive dynamics of             • Summary
  • Rosacea                                        corticosteroid treatment classes    • Introduction
     - Overview                                  - Leading brands of corticosteroid    • Company market shares
     - Diagnosis, treatment and                    treatments                          • Novartis
       management                                - Corticosteroid treatments market       - Overview
     - Epidemiology                                analysis
                                                                                          - Sales focus by drug class
     - Forecast epidemiology                         - Market dynamics
                                                                                          - Marketed product portfolio
        - Depression                                 - Key brands analysis
                                                                                          - R&D pipeline analysis
     - Regulation                                - Corticosteroid treatment sales
        - Governmental initiatives                 forecasts to 2011                      - Strategic and growth analysis
        - Advertising to children            •   Anti-infective treatments                   - Drivers of growth
        - Labeling                               - Market analysis by drug class             - Resistors of growth
        - Taxation                               - Leading brands of anti-infective    • GlaxoSmithKline
  • Conclusions                                    treatments                             - Overview
                                                     - Market dynamics                    - Sales focus by drug class
  CHAPTER 2: GLOBAL MARKET                           - Key brands analysis                - Marketed product portfolio
  ANALYSIS                                       - Anti-infective treatment sales         - R&D pipeline analysis
  • Summary                                        forecasts to 2011
                                                                                          - Strategic and growth analysis
  • Introduction                             •   Other dermatologic treatments
                                                                                             - Drivers of growth
  • Market analysis by country                   - Leading brands of other
  • Licensing trends                                                                         - Resistors of growth
                                                   dermatologic treatments
  • Market analysis by drug class                    - Key brands analysis             • Schering-Plough
  • Leading brands dynamics                      - Other dermatologic treatments          - Overview
  • Key events in the dermatology                  sales forecasts to 2011                - Sales focus by drug class
     market                                  •   Total Therapeutic market sales           - Marketed Product Portfolio
                                                 forecasts to 2011                        - R&D pipeline analysis
                                                                                          - Strategic and growth analysis
                                                                                                                 B u s i n e s s I n s i g h ts   5




The Dermatology Market Outlook to 2011


            - Drivers of growth         LIST OF FIGURES (ABRIDGED)                LIST OF TABLES (ABRIDGED)
            - Resistors of growth       • Typical treatment                       • Estimated prevalence of
  •   Sanofi-Aventis                       patterns in the treatment of acne         dermatological conditions in the
      - Overview                        • Typical treatment patterns in the          seven major pharmaceutical
      - Sales focus by drug class          treatment of psoriasis                    markets, 2005
      - Marketed product portfolio      • Global dermatology market share         • Estimated prevalence of clinical
      - R&D pipeline analysis              by geography, 2005                        acne across seven major markets,
      - Strategic and growth analysis   • Sales of types of dermatology              2005
            - Drivers of growth            brands, 2004-5                         • Forecast epidemiology of clinical
            - Resistors of growth       • Competitive dynamics of the                acne across the seven major
  •   Johnson & Johnson                    global dermatology market by              markets, 2005-11
      - Overview                           drug class, 2005                       • Estimated prevalence of psoriasis
      - Sales focus by drug class       • Competitive dynamics of the                across seven major markets, 2005
      - Marketed product portfolio         leading 10 brands in the global        • Forecast epidemiology of psoriasis
      - R&D pipeline analysis              dermatology market, 2004-5                across the seven major markets,
      - Strategic and growth analysis   • Competitive dynamics of                    2005-11
            - Drivers of growth            subclasses in the acne treatments      • Estimated prevalence of infectious
            - Resistors of growth          market, 2004-5                            diseases (viral) of the skin across
  •   Bayer Schering Pharma             • Competitive dynamics of the                seven major markets, 2005
      - Overview                           leading acne treatments in the         • Estimated prevalence of infectious
      - Sales focus by drug class          global dermatology market,                diseases (fungal) of the skin
      - Marketed product portfolio         2004-5                                    across seven major markets, 2005
      - R&D pipeline analysis           • Competitive dynamics of the             • Estimated prevalence of infectious
      - Strategic and growth analysis      leading oral acne treatments in           diseases (bacterial) of the skin
            - Drivers of growth            the global dermatology market,            across seven major markets, 2005
            - Resistors of growth          2004-5                                 • Forecast epidemiology of
  •   Stiefel Labs                      • Competitive dynamics of the                infectious diseases (viral) of the
      - Overview                           leading topical acne treatments           skin across the seven major
      - Sales focus by drug class          in the global dermatology market,         markets, 2005-11
      - Marketed product portfolio         2004-5                                 • Forecast epidemiology of
      - R&D pipeline analysis           • Competitive dynamics of classes in         infectious diseases (fungal) of the
      - Strategic and growth analysis      the psoriasis treatments market,          skin across the seven major
            - Drivers of growth            2004-5                                    markets, 2005-11
            - Resistors of growth       • Competitive dynamics of the             • Forecast epidemiology of
  •   Roche                                leading psoriasis treatments in           infectious diseases (bacterial) of
      - Overview                           the global dermatology market,            the skin across the seven major
      - Sales focus by drug class          2004-5                                    markets, 2005-11
      - Marketed product portfolio      • Competitive dynamics of classes in      • Estimated prevalence of atopic
      - R&D pipeline analysis              the corticosteroid treatments             dermatitis across seven major
      - Strategic and growth analysis      market, 2004-5                            markets, 2005
            - Drivers of growth         • Competitive dynamics of the             • Forecast epidemiology of
            - Resistors of growth          leading corticosteroid treatments         dermatitis across the seven major
  •   Nestlé/L’Oréal                       in the global dermatology                 markets, 2005-11
      - Overview                           market, 2004-5                         • Estimated prevalence of rosacea
      - Sales focus by drug class       • Competitive dynamics of                    across seven major markets, 2005
      - Marketed product portfolio         subclasses in the anti-infective       • Forecast epidemiology of rosace
      - R&D pipeline analysis              treatments market, 2004-5                 across the seven major markets,
      - Strategic and growth analysis   • Competitive dynamics of the                2005-11
            - Drivers of growth            leading anti-infective treatments in
            - Resistors of growth          the global dermatology market,
                                           2004-5
  CHAPTER 5: APPENDIX
                                                                                                            FAX BACK TO: +44 (0) 207 900 6688
                                                                                                                                                            or scan and e-mail to
                                                                                                                                           marketing@globalbusinessinsights.com


      I would like to order the following report...                                                    1         Company details                                                                     3
  (Please use BLOCK CAPITALS)
                                                                                                           Company name: ________________________________________________________
  ______________________________________________________
                                                                                                           EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number:
  ______________________________________________________
                                                                                                           _____________________________________________________________________________________________

      Hard Copy (extra £50/€75/$95)                     Interactivity (extra £50/€75/$95)
      Please allow 28 days for delivery                 Search, customize & translate content              Purchase Order Number (if required)_____________________________________



      Please select a license type:                                                                    2         Payment method                                                                     4
                                                      GB£              EUR              US$
                                                                                                           Please indicate your preferred currency:           GB£        EUR           US$
            Single User
                                                      1495            2160             2875
            (eCopy)                                                                                        Total order value is ____________________________
            Access permitted for one individual only
                                                                                                                  I will forward a check payable to Business Insights Limited.

           Site                                                                                                   Please invoice my company (please complete invoice address below)
                                                     2995            4330             5750
           License                                                                                                I would like to pay by bank transfer (email address required)
            Access permitted for every individual based at one location
                                                                                                                  Debit my credit/charge card:              Amex              Visa            Mastercard

           Company
                                                     5600            8100            10795                 Card No________________________________________________________________________
           License
            Global access for every individual member of staff at the company
                                                                                                            Expiry Date _________ / _________ Signature ______________________________
                  To ask a question about license types, email: marketing@globalbusinessinsights.com



       Communications Feedback                                                                                   Payor details                                                                      5
  Please let us know if any of the following factors influenced your purchase...
                                                                                                           Title: Mr/Mrs/Ms                            (Please use BLOCK CAPITALS)
         Email/Fax/Postal promotion                      Trade Press
         Brochure                                        My Account Manager                                First Name:                                 Last Name:
         Table of Contents                               Conference materials
         Colleague Recommendation                        Website/web search                                Email

                                                                                                           Job Title
      Recipient details (If different from Payor)
                                                                                                           Department
Title: Mr/Mrs/Ms                                (Please use BLOCK CAPITALS)
                                                                                                           Address
First Name:                                     Last Name:

Email
                                                                                                           City                                   State/Province
Job Title
                                                                                                           Country                                Post Code/ZIP
Department
                                                                                                           Tel
Address
                                                                                                           Fax
City                                       State/Province
                                                                                                           Sign here to confirm your order:
Country                                    Post Code/ZIP

Tel                                           Fax
                                                                                                           ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:632
posted:7/26/2010
language:English
pages:7
Description: The Dermatology market Outlook to acne